Adial Pharmaceuticals Warrant
ADILW
ADILW was delisted on the 27th of July, 2023.
1 hedge funds and large institutions have $2K invested in Adial Pharmaceuticals Warrant in 2020 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
100% more capital invested
Capital invested by funds: $1K → $2K (+$1K)
0% more funds holding
Funds holding: 1 → 1 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$93 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $2K | -$93 | -358 | -4% |
|
ADILW Hedge Fund Activity: Q2 2020 in Review
1 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals Warrant (ADILW) for Q2 2020, worth a combined $2K — up 100% from $1K a quarter earlier.
Fund positioning in ADILW was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $93.
- 1 institutional investor held Adial Pharmaceuticals Warrant (ADILW) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $2K of Adial Pharmaceuticals Warrant stock for Q2 2020, up 100% quarter-over-quarter.
- 0 funds opened new Adial Pharmaceuticals Warrant positions in Q2 2020 and 0 closed out.
- The largest Adial Pharmaceuticals Warrant seller in Q2 2020 was UBS Group, an estimated $93 sold.
Based on aggregated 13F filings for Q2 2020.